Select country set
Menu Shopping cart 0,00 Search

Rabbit IgG Anti SARS-CoV-2 Spike (S1) Antibody, Clone: CR3022

  • Regulatory status:RUO
  • Type:Recombinant Monoclonal Antibody
  • Other names:Severe acute respiratory syndrome coronavirus 2 spike glycoprotein S1, 2019 novel coronavirus S1 protein, SARS-CoV-2 S1 subunit, COVID-19
  • Species:Rabbit
Please select your region to see available products and prices.
Cat. No. Size Price

New RM812424100 0.1 mg
PubMed Product Details
Technical Data


Recombinant Monoclonal Antibody




IgG, kappa




This is a recombinant monoclonal antibody. It is a reformatted antibody made using the variable domain sequences of the original Human IgG1 format. The original monoclonal antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV.

Amino Acid Sequence

Antibody binds to both SARS-CoV and SARS-CoV-2 (COVID-19) with high affinity at amino acids 318-510 in the S1 domain of the Spike protein.

Species Reactivity

SARS-CoV and SARS-CoV-2 (COVID-19)

Purification Method

Affinity chromatography on a column with immobilized protein A.

Antibody Content

0.1 mg; concentration: 1.0 mg/ml For actual concentration see the Certificate of Analysis.


Supplied as a liquid in PBS, 0.02% Proclin 300.


ELISA, Crystallography, NTRL


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Short Term Storage: Up to 3 months at +4ºC Long Term Storage: -20ºC


Products are for Research Use or for Further Manufacturing Use only. Not for Diagnostic or Therapeutic Use.


Research topic

Immune Response, Infection and Inflammation, COVID-19


Coronaviruses (CoVs), within the order Nidovirales, are enveloped, single-strand, positive-sense RNA viruses with a large genome of approximately 30 kbp in length. A human infecting coronavirus (viral pneumonia) initially known as 2019 novel coronavirus (2019-nCoV) was found in the fish market at the city of Wuhan, Hubei province of China in December 2019. The virus is now named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
SARS-CoV-2 shares an 87% identity to the 2 bat-derived severe acute respiratory syndrome 2018 SARS-CoV-2 located in Zhoushan of eastern China. SARS-CoV-2 has an analogous receptor-BD-structure to that of 2018 SARS-CoV, even though there is a.a. diversity so thus the SARS-CoV-2 might bind to ACE2 receptor protein (angiotensin-converting enzyme 2) in humans.

While bats are possibly the host of SARS-CoV-2, researchers suspect that animal from the ocean sold at the seafood market was an intermediate host. RSCU analysis proposes that the SARS-CoV-2 is a recombinant within the viral spike glycoprotein between the bat coronavirus and an unknown coronavirus.

Coronaviruses contain at least four structural proteins: Spike (S) protein, envelope (E) protein, membrane (M) protein, and nucleocapsid (N) protein.
The spike (S) glycoprotein is a type I transmembrane glycoprotein that plays an important role in mediating viral infection and is common to all HCoVs. The S proteins consist of two subunits, S1 and S2. The S1 subunit binds the cellular receptor through its receptor-binding domain (RBD), followed by conformational changes in the S2 subunit, which allows the fusion peptide to insert into the host target cell membrane. The heptad repeat 1 (HR1) region in the S2 subunit forms a homotrimeric assembly, which exposes three highly conserved hydrophobic grooves on the surface that bind heptad repeat 2 (HR2). This six-helix bundle (6-HB) core structure is formed during the fusion process and helps bring the viral and cellular membranes into close proximity for viral fusion and entry. Thus, the S protein is an important target protein for the development of specific drugs.

Related Products Docs